26th Jul 2010 07:00
Eco Animal Health Group plc
ECO Animal Health Group is pleased to report that following a successful Good Manufacturing Practice (GMP) inspection, the US Federal Drug Administration (FDA) has approved ECO's manufacturing facility in China, which produces the Aivlosin® Active Pharmaceutical Ingredient. FDA approval of this facility, which has already been approved by the EU and Japanese regulatory authorities, marks a very important milestone in the development and registration programme for Aivlosin® in the USA.
The company also announces that it will release its results for the year ended 31 March 2010 on 10 August 2010.
Contacts:
| ECO Animal Health Group plc | Marc Loomes 020 8447 8899 | |
| Spiro Financial | Anthony Spiro 020 8336 6196 | |
| Cenkos Securities plc | Stephen Keys/Liz Bowman 020 7397 8926 |
(Nominated Adviser)
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
Copyright Business Wire 2010
Related Shares:
Eco Animal